FCF Healthcare & Life Sciences Venture Capital Monitor – Europe – 06/2023 published

FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Healthcare & Life Sciences Venture Capital Monitor – Europe 06/2023”. The Monitor is a monthly published overview of venture capital trends in the European Life Sciences sector.

As of the end of June 2023 we identify the following current VC trends in Europe:

  • In 2023, overall Life Sciences funding has reached EUR 4,865m
  • Biotech received 47% of the total investment volume (+2% compared to the previous month)
  • Oncology dominates as the top indication in Biotechnology
  • Ellipses Pharma (United Kingdom) has the highest transaction volume of EUR 126m in June, followed by Beacon Therapeutics (United Kingdom) EUR 111m and Corwave (France) EUR 61m 
  • Revival Healthcare Capital (United States) dominates the Top 5 Investors (by deal volume), followed by European Innovation Council Fund (Belgium) and Gilde Healthcare Partners (Netherlands)
  • Top 5 Deals exceed EUR 120m each, the largest transaction amounted to EUR 683m in YgEia3 (United Kingdom)

To access the full report, please click here.

By Mathias KlozenbücherJohannes Link and Marco Buonafede-Bennardo.